BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29100813)

  • 1. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.
    Boormans JL; Mayor de Castro J; Marconi L; Yuan Y; Laguna Pes MP; Bokemeyer C; Nicolai N; Algaba F; Oldenburg J; Albers P
    Eur Urol; 2018 Mar; 73(3):394-405. PubMed ID: 29100813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
    Boormans JL; Sylvester R; Anson-Cartwright L; Glicksman RM; Hamilton RJ; Hahn E; Daugaard G; Lauritsen J; Wagner T; Avuzzi B; Nicolai N; Del Muro XG; Aparicio J; Stalder O; Rothermundt C; Fischer S; Laguna MP
    Eur Urol Oncol; 2024 Jun; 7(3):537-543. PubMed ID: 37951820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review.
    Zengerling F; Kunath F; Jensen K; Ruf C; Schmidt S; Spek A
    Urol Oncol; 2018 Oct; 36(10):448-458. PubMed ID: 28712790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
    Warde P; Specht L; Horwich A; Oliver T; Panzarella T; Gospodarowicz M; von der Maase H
    J Clin Oncol; 2002 Nov; 20(22):4448-52. PubMed ID: 12431967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.
    Chung P; Daugaard G; Tyldesley S; Atenafu EG; Panzarella T; Kollmannsberger C; Warde P
    Cancer Med; 2015 Jan; 4(1):155-60. PubMed ID: 25236854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort.
    Soper MS; Hastings JR; Cosmatos HA; Slezak JM; Wang R; Lodin K
    Am J Clin Oncol; 2014 Aug; 37(4):356-9. PubMed ID: 23275274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the Key Proteins Associated with Rete Testis Invasion in Clinical Stage I Seminoma via Label-Free Quantitative Mass Spectrometry.
    Borszéková Pulzová L; Roška J; Kalman M; Kliment J; Slávik P; Smolková B; Goffa E; Jurkovičová D; Kulcsár Ľ; Lešková K; Bujdák P; Mego M; Bhide MR; Plank L; Chovanec M
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology.
    Bilici A; Ozturk T; Turkmen E; Odabas H; Cihan S; Selcukbiricik F; Erdogan B; Urakci Z; Kandemir N; Bayoglu IV; Demirci U; Duran AO; Sendur MA; Yavuzer D; Harputluoglu H; Kavgaci H; Gumus M
    World J Urol; 2015 Oct; 33(10):1613-22. PubMed ID: 25605506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance--protocol for a systematic review.
    Kunath F; Spek A; Jensen K; Zengerling F; Schmidt S
    Syst Rev; 2015 Dec; 4():182. PubMed ID: 26684760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tumour size and rete testis invasion in progression free survival of our patients with stage i testicular seminoma. A retrospective observational study of a reference hospital center and literature review.
    Yáñez-Castillo YM; Melgarejo-Segura MT; Gutiérrez-Tejero F; Arrabal-Martín M
    Actas Urol Esp (Engl Ed); 2023 Dec; 47(10):654-660. PubMed ID: 37355209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).
    Aparicio J; Maroto P; García Del Muro X; Sánchez-Muñoz A; Gumà J; Margelí M; Sáenz A; Sagastibelza N; Castellano D; Arranz JA; Hervás D; Bastús R; Fernández-Aramburo A; Sastre J; Terrasa J; López-Brea M; Dorca J; Almenar D; Carles J; Hernández A; Germà JR
    Ann Oncol; 2014 Nov; 25(11):2173-2178. PubMed ID: 25210015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testicular seminoma clinical stage 1: treatment outcome on a routine care level.
    Dieckmann KP; Dralle-Filiz I; Matthies C; Heinzelbecker J; Bedke J; Ellinger J; Anheuser P; Souchon R; Pichlmeier U;
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1599-607. PubMed ID: 27116691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance of stage I testicular seminoma: 20 years oncological results].
    Zores T; Mouracade P; Duclos B; Saussine C; Lang H; Jacqmin D
    Prog Urol; 2015 Apr; 25(5):282-7. PubMed ID: 25724863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study.
    Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Rosenvilde JJ; Berney D; Daugaard G
    J Clin Oncol; 2024 Jan; 42(1):81-89. PubMed ID: 37683134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).
    Tandstad T; Ståhl O; Dahl O; Haugnes HS; Håkansson U; Karlsdottir Å; Kjellman A; Langberg CW; Laurell A; Oldenburg J; Solberg A; Söderström K; Stierner U; Cavallin-Ståhl E; Wahlqvist R; Wall N; Cohn-Cedermark G;
    Ann Oncol; 2016 Jul; 27(7):1299-304. PubMed ID: 27052649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy.
    Kobayashi K; Saito T; Kitamura Y; Nobushita T; Kawasaki T; Hara N; Takahashi K
    Diagn Pathol; 2013 Apr; 8():57. PubMed ID: 23566361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage I testicular seminoma risk-adapted therapeutic management.
    Mrinakova B; Kajo K; Lehotska V; Ondrusova M; Balogova S; Pinakova Z; Novotna V; Usakova V; Fedorkova L; Waczulikova I; Kausitz J; Ondrus D
    Neoplasma; 2021 May; 68(3):613-620. PubMed ID: 33502887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological risk factors for higher clinical stage in testicular seminomas.
    Trevino KE; Esmaeili-Shandiz A; Saeed O; Xu H; Ulbright TM; Idrees MT
    Histopathology; 2018 Nov; 73(5):741-747. PubMed ID: 29858564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
    Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
    World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study.
    Aparicio J; Sánchez-Muñoz A; Gumà J; Domenech M; Meana JA; García-Sánchez J; Bastús R; Gironés R; González-Billalabeitia E; Sagastibelza N; Ochenduszko S; Sánchez A; Terrasa J; Germà-Lluch JR; García Del Muro X;
    Oncology; 2018; 95(1):8-12. PubMed ID: 29587278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.